Bausch Health/$BHC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Bausch Health
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
- Ticker
- $BHC
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 20,300
- Headquarters
- Laval, Canada
- Website
- www.bauschhealth.com
Bausch Health Metrics
BasicAdvanced
$2.2B
-
-$2.95
0.38
-
Price and volume
Market cap
$2.2B
Beta
0.38
52-week high
$8.00
52-week low
$4.33
Average daily volume
2.2M
Financial strength
Current ratio
1.435
Quick ratio
0.9
Long term debt to equity
-24.81
Total debt to equity
-19.219
Interest coverage (TTM)
1.70%
Profitability
EBITDA (TTM)
3,908
Gross margin (TTM)
71.45%
Net profit margin (TTM)
-10.12%
Operating margin (TTM)
25.21%
Effective tax rate (TTM)
-49.32%
Revenue per employee (TTM)
$530,000
Management effectiveness
Return on assets (TTM)
6.57%
Return on equity (TTM)
333.74%
Valuation
Price to revenue (TTM)
0.202
Price to book
-1.07
Price to tangible book (TTM)
-0.14
Price to free cash flow (TTM)
1.576
Free cash flow yield (TTM)
63.46%
Free cash flow per share (TTM)
3.738
Growth
Revenue change (TTM)
10.09%
Earnings per share change (TTM)
-1,228.72%
3-year revenue growth (CAGR)
9.13%
10-year revenue growth (CAGR)
0.49%
3-year earnings per share growth (CAGR)
79.08%
10-year earnings per share growth (CAGR)
0.17%
What the Analysts think about Bausch Health
Analyst ratings (Buy, Hold, Sell) for Bausch Health stock.
Analyst projections of the future price of Bausch Health stock.
Bulls say / Bears say
Operating momentum is strong: second-quarter revenue rose 13% organically adjusted growth was 11%, adjusted EBITDA rose 28%, and management raised its 2026 outlook. The business excluding Bausch + Lomb has now delivered 13 consecutive quarters of year-on-year revenue and adjusted EBITDA growth. (Bausch Health)
Growth is becoming broader than the core Xifaxan franchise. Solta Medical revenue rose 38% in the second quarter, while International revenue also grew strongly, helped by China distribution integration, EMEA expansion and new product launches. (Bausch Health, Bausch Health)
Bausch Health still owns about 87% of Bausch + Lomb, creating a potential value-unlocking catalyst if management can complete a separation or monetise part of the holding. The appointment of Bausch Health’s chief executive to the Bausch + Lomb board shows the parent is actively shaping that asset’s strategy. (Bausch Health, StockTitan)
Bausch Health remains highly leveraged, with about $20.2 billion of debt principal and $798 million of first-half interest expense. Refinancing still matters, and the planned Bausch + Lomb separation depends on meeting leverage targets and securing approvals. (StockTitan, CreditSights)
Xifaxan is the main Salix growth engine, but its future is exposed to generic competition. Lotus said a court ruling could lead to final FDA approval for Norwich’s generic rifaximin, putting a major revenue stream at risk. (Lotus Pharmaceutical, Bausch Health)
The first half produced a $1.17 billion attributable loss and a large Salix goodwill impairment following failed Phase 3 trials, leaving shareholders’ equity in deficit. This highlights the risk that clinical setbacks and weaker product prospects can destroy reported value even when adjusted earnings are growing. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
Bausch Health Financial Performance
Revenues and expenses
Bausch Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Bausch Health News
AllArticlesVideos
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
Business Wire3 days ago
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
Business Wire2 months ago
Bausch Health Cos Q2 Earnings Call Highlights
MarketBeat3 months ago
Funds containing Bausch Health
AllUSDEURGBP
Fund name | Fund size | $BHC weighting |
|---|---|---|
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.02% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.02% |
Vanguard ESG Global All Cap€V3AA | €1.1B | 0.00% |
Vanguard ESG Global All Cap£V3AB | £905M | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.